Research Comparison
CJC-1295 (without DAC) vs GHRP-2
A side-by-side research comparison of CJC-1295 (without DAC) and GHRP-2 drawn from Cedar Peptides' peptide database records.
CJC-1295 (without DAC)
CJC-1295 (without DAC), also known as Modified GRF 1-29 (Mod GRF 1-29), is a short-acting synthetic analog of growth hormone releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone (GH) release in a pulsatile, physiologically consistent manner. Unlike the DAC-modified version, this variant has a very short half-life, allowing precise control over GH pulses and reducing the risk of receptor desensitization. It is primarily used in research focused on recovery, anti-aging, body composition, and endocrine function optimization.
GHRP-2
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide belonging to the growth hormone secretagogue (GHS) class. It stimulates the release of endogenous growth hormone (GH) primarily through activation of the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary. Unlike GHRH analogs, GHRP-2 acts via a distinct pathway, making it highly synergistic when combined with GHRH-based peptides. It is widely used in research to investigate growth hormone pulsatility, appetite signalling, and metabolic regulation.
Reading a comparison
A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.